Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implications for Alzheimer&...
Dutch Health Insurance Rejects Lecanemab Coverage
Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basic health insurance package, marking a key lecanema...
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
European Commission Backs Wegovy Obesity Treatment with 7.2 mg Dose
The European Commission has approved a higher 7.2 mg maintenance dose of
Revised MenACWY Vaccination Strategy for Adolescents in Germany
G-BA Approves MenACWY Vaccination Strategy Shift for Adolescents
Germany's Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) has approved key amendments to the Protective Vaccination Directive on December 18...